| Previous Close | 4.25 |
| Open | 4.25 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 900 |
| Day's Range | 4.25 - 4.45 |
| 52 Week Range | 3.25 - 5.75 |
| Volume | 50,514 |
| Avg. Volume | 86,353 |
| Market Cap | 78.862M |
| Beta | 2.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings Date | Feb 6, 2018 - Feb 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.80 |
Q4 2018 Applied Genetic Technologies Corp Earnings Call
Warning! GuruFocus has detected 2 Warning Signs with AGTC. For the last quarter Applied Genetic Technologies Corp reported a revenue of $3.60 million, compared with the revenue of $8.39 million during the same period a year ago. The Applied Genetic Technologies Corp had an operating margin of -92.55%, compared with the operating margin of 4.82% a year before.
The Alachua, Florida-based company said it had a loss of 37 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 10, 2018-- Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies ...
Applied Genetic Tech (NASDAQ: AGTC ) announces its next round of earnings Monday, Sept. 10. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement. Earnings, Revenue Based ...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 30, 2018-- Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies ...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 08, 2018-- Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies ...
Achroma Corp., a non-profit 501(c)(3) tax-exempt charity dedicated to raising awareness and finding a cure for a rare form of blindness called Achromatopsia, announced results of a new global survey, Understanding the Achromatopsia Patient Experience. NASDAQ: AGTC), the gene therapy company, was distributed through Achroma Corp’s network and received 226 responses from individuals who have been diagnosed – or have a child who has been diagnosed – with Achromatopsia, a rare inherited retinal disorder that is associated with a significant reduction in visual acuity, extreme light sensitivity causing day blindness, and complete loss of color discrimination.
Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has enrolled the first patient of the second cohort in the company’s Phase 1/2 clinical trial evaluating the safety and efficacy of an investigational AAV-based gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP). Under the terms of its collaboration with Biogen (BIIB), AGTC will receive a milestone payment of $10 million.
Q3 2018 Applied Genetic Technologies Corp Earnings Call
The Alachua, Florida-based company said it had a loss of 45 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Stock Monitor: Applied Genetic Technologies Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 12, 2018 / Active-Investors.com has just released a free research report on Catalyst Biosciences, ...
Q2 2018 Applied Genetic Technologies Corp Earnings Call
The Alachua, Florida-based company said it had a loss of 29 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
NEW YORK, NY / ACCESSWIRE / February 9, 2018 / Applied Genetic Technologies Corp. (NASDAQ: AGTC ) will be discussing their earnings results in their Q2 Earnings Call to be held on February 9, 2018 at 8:00 ...